Find clinical trials for Leukemia in Barcelona, CT
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Leukemia trials near Barcelona, CT, ESP:
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Barcelona, Spain and 51 other locations
in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...
Phase 2
Barcelona, Spain and 173 other locations
Phase 2 dose (RP2D) of SNDX-5613 in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Hospitalet De Llobregat, Spain and 47 other locations
(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...
Phase 3
Barcelona, Spain and 105 other locations
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-75276617 in Part 1 (Dose Escalation) and to determine safe...
Phase 1, Phase 2
Barcelona, Spain and 23 other locations
this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias...
Phase 1, Phase 2
Barcelona, Spain and 31 other locations
a standard of care for patients with newly diagnosed acute myeloid leukemia not eligible for intensive chemotherapy (thus not eligible for a...
Phase 3
Barcelona, Spain and 63 other locations
agents in participants with relapsed or refractory acute myeloid leukemia and relapsed or refractory and treatment-naive higher risk melodys...
Phase 1
Barcelona, Spain and 31 other locations
The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acu...
Phase 1, Phase 2
Barcelona, Spain and 11 other locations
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...
Phase 2
Barcelona, Spain and 85 other locations
Clinical trials
Research sites
Resources
Legal